Alcon Acquired by Novartis
On December 15, 2010, Novartis (NYSE: NVS) agreed to acquire the remaining shares of Alcon, Inc. (NYSE: ACL) it doesn't currently own for $168 per share.
The merger consideration will be comprised of a combination of Novartis shares and, if necessary, a cash contingent value amount to result in a total value of $168 per share.
Upon completion of the merger, Alcon will become the second largest division within Novartis. CIBA VISION and select Novartis ophthalmic medicines will be integrated into Alcon, forming an organization with more than $8.7 billion in sales covering over 70 percent of the eye care segment.
The merger consideration will be comprised of a combination of Novartis shares and, if necessary, a cash contingent value amount to result in a total value of $168 per share.
Upon completion of the merger, Alcon will become the second largest division within Novartis. CIBA VISION and select Novartis ophthalmic medicines will be integrated into Alcon, forming an organization with more than $8.7 billion in sales covering over 70 percent of the eye care segment.
View Older Stories View More Recent Stories
-
European shares hit by U.S. tariff threat, growth jitters
-
Novartis continues transformation into a leading medicines company with completion of the Alcon spin-off
-
Alcon Debuts as Independent, Publicly Traded Company
-
Alcon Debuts as Independent, Publicly Traded Company
-
Cleveland Research Starts Alcon Inc. (ALC) at Neutral
-
Novartis's Alcon spinoff ousts Baer from Swiss benchmark SMI
-
Alcon Announces Timothy Stonesifer as Chief Financial Officer
-
Alcon Announces Timothy Stonesifer as Chief Financial Officer
-
Adverum Biotechnologies Appoints Ophthalmology Industry Veteran Aaron Osborne, MBBS MRCOphth, as Chief Medical Officer
-
Novartis says listing of Alcon eye care business expected on April 9
-
Novartis plans for Alcon spin-off on April 9, 2019
-
Alcon Announces Acquisition of PowerVision, Inc.
-
Novartis generics boss quits amid conjecture over business's future
-
Oxurion NV Business Update - FY 2018
-
Oxurion NV Business Update - FY 2018
-
Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
-
Novartis faces shareholder criticism over drug prices at AGM
-
Hill Holliday Launches Hill Holliday Health
-
Novartis issues summary financial information for the Alcon eye care business ahead of shareholder vote on proposed spin-off
-
Alcon Debuts iLux® MGD Treatment System for Personalized Therapy for Dry Eye Disease at SECO International 2019 Annual Meeting
-
Novartis CEO lauds Trump administration plan to overhaul rebates
-
Graybug Vision Appoints Frédéric Guerard as Chief Executive Officer
-
Novartis delivered strong sales growth with core margin expansion, built leading advanced therapy platforms and focused the company in 2018
-
Minimally Invasive Glaucoma Surgery (MIGS) Devices Market to Reach a Market Size of $1,180.7 Million by 2024 - KBV Research
-
Alcon Announces Acquisition of Tear Film Innovations, Inc.
-
Outlook Therapeutics Provides Business Update and Reports Financial Results for Fiscal Year 2018
-
Alcon, Elara and Microsoft Introduce Educational Virtual Reality Application
-
iChek Adds New Advisory Board Member
-
ProQR Announces Strategic Changes to the Management Team and Key New Hires
-
Oncobiologics Changes Name to Outlook Therapeutics; Announces Next Steps in Executing ONS-5010 Clinical and Regulatory Strategy
-
Alcon to highlight its vision, strategy and benefits as a standalone company to investors and analysts in New York and London
-
Oculis Strengthens its Global Clinical and Business Development Capabilities Through Strategic Appointments to Senior Management Team
-
Alphabet unit halts glucose-detecting contact lens project
-
Generex Announces Appointment of Executive Management Team
-
Santen Expands Research and Development Leadership Team with Additions of Reza M. Haque, MD, PhD and Peter Sallstig, MD, MBA
-
Alcon files initial Form 20-F registration statement with SEC for proposed spinoff; plans investor days in New York and London
-
Clearside Biomedical Announces Third Quarter 2018 Financial Results and Provides Corporate Update
-
Clearside Biomedical Announces Third Quarter 2018 Financial Results and Provides Corporate Update
-
iChek Creates New Medical Advisory Board
-
Notal Vision Announces Appointment of Dr. Susan Orr as Chief Executive Officer
-
Alcon to develop SMART Suite digital health platform for cataract surgery
-
Novartis delivered strong growth and innovation during the third quarter, including progressing advanced therapy platforms to drive future growth
-
Lynn Winterton, Ph.D., Pioneering Contact Lens Inventor, Named to OcuMedic, Inc. Scientific Advisory Board
-
Alcon AIR OPTIX® COLORS Contact Lenses Launches Sweepstakes that Gives People Permission to Play with Eye Color This Fall
-
Top Employers Institute Releases the Coveted List of Africa's Top Employers 2019
-
Alcon introduces enhanced WaveLight® Refractive Suite to optimize the patient and surgeon LASIK experience
-
Novartis to cut 2,550 jobs in Switzerland, UK in profit push
-
Oculis Appoints World-renowned Ophthalmology Specialist
-
Launch of Alcon Experience Academy Reinforces Commitment to Training and Education for Eye Care Professionals
-
LifeMax Appoints Laman Alani, Ph.D., as VP of Product Development

